Brokerages Set Tango Therapeutics, Inc. (NASDAQ:TNGX) PT at $12.20

Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) has been given an average recommendation of "Buy" by the six ratings firms that are currently covering the stock, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $12.20.

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $13.00 target price on shares of Tango Therapeutics in a research report on Monday, April 14th.

Tango Therapeutics Trading Up 1.8%

NASDAQ TNGX traded up $0.09 during trading on Friday, hitting $5.01. The company had a trading volume of 9,008,178 shares, compared to its average volume of 1,565,223. Tango Therapeutics has a one year low of $1.03 and a one year high of $12.02. The company has a market cap of $543.03 million, a price-to-earnings ratio of -4.11 and a beta of 1.24. The company's fifty day moving average is $2.75 and its 200-day moving average is $2.50.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.02). The company had revenue of $5.39 million during the quarter, compared to the consensus estimate of $6.73 million. Tango Therapeutics had a negative return on equity of 62.75% and a negative net margin of 322.67%. As a group, equities analysts anticipate that Tango Therapeutics will post -1.19 EPS for the current year.

Hedge Funds Weigh In On Tango Therapeutics

Several institutional investors have recently made changes to their positions in the business. TCG Crossover Management LLC purchased a new stake in Tango Therapeutics during the 4th quarter valued at approximately $33,174,000. Boxer Capital Management LLC purchased a new position in shares of Tango Therapeutics in the fourth quarter valued at $32,077,000. Gilead Sciences Inc. purchased a new position in shares of Tango Therapeutics in the fourth quarter valued at $15,000,000. Farallon Capital Management LLC purchased a new position in Tango Therapeutics during the fourth quarter worth $12,360,000. Finally, Nantahala Capital Management LLC purchased a new position in Tango Therapeutics during the fourth quarter worth $8,666,000. Institutional investors own 78.99% of the company's stock.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.